Inflammasome Treatment against Adverse Events of Special Interest

BackgroundAdverse events of special interest (AESI) are associated with an elevated risk of myocarditis, lymphadenopathy, and death. Main body of the abstractWe found a supplement that might reduce the risk of AESI induced by SARS-CoV-2 spike protein. The number of cases of AESI was reported to have the same patterns in the UK, South Korea, and Trials of mRNA vaccines among nine countries. The spike protein of SARS-CoV-2 damages hematopoietic stem/progenitor cells in an NLRP3 inflammasome-dependent manner. AESI might come from inflammasomes induced by mRNA vaccines expressing the full-length prefusion spike glycoprotein of SARS-CoV-2. Inflammasomes induced by the mRNA vaccine can induce AESI or biopsy‑proven lymphocytic myocarditis. Dapsone has been used to treat stroke, infective endocarditis, immune thrombocytopenia, Alzheimer's disease, seizure, and COVID-19 ARDS. As an inflammasome competitor, dapsone can reduce inflammasome reactions.ConclusionInflammasomes induced by mRNA vaccines can induce AESI or other inflammasome diseases, such as COVID-19. As an inflammasome competitor, dapsone can reduce inflammasome reactions.